Catalent Announces Two Senior Appointments to Expand Biologics Business
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced two senior appointments to further strengthen its global biologics business.
Andrew Sandford joins Catalent as Vice President Business Development, Biologics, and will focus on growth of the company’s existing biologics offerings, including the recently completed Biomanufacturing Center of Excellence in Madison, WI, and its high-performance production cell line offering based on the proprietary GPEx system, as well as Catalent’s new SMARTag ADC technology. In addition, he will focus on driving global business and licensing opportunities to deliver sustainable long-term growth.
Mr Sandford previously served as the Vice President of Business Development for Selexis, Inc., a subsidiary of Selexis SA, where he established the US subsidiary of the company and was responsible for global transactional and strategic value creation.
Prior to this, he worked with Dow Chemical's Ventures Business Unit; Dowpharma, and Cambrex Biopharma, which was latterly acquired by Lonza Biologics.
A microbiologist by education, Mr Sandford holds a BS from the State University of New York at Plattsburgh.
In a newly created role, Catalent has also appointed Dr Jennifer Mitcham as Director, Business Development for Antibody-Drug Conjugates (ADC), Biologics.
Dr Mitcham will focus on driving the development pipeline and global customer base for the SMARTag ADC technology platform. She joins Catalent from Theraclone Sciences where she was Senior Director, Program Management, responsible for the development of the lead clinical antibody therapeutic program. Prior to Theraclone, Dr Mitcham was with Corixa Corporation where she managed the oncology antibody development portfolio and was a Group Leader in Tumor Antigen Discovery.
Dr Mitcham conducted her postdoctoral research at Immunex Corp, now Amgen, and holds both a BS in Biochemistry & Biophysics from Texas A&M University and a PhD in Molecular Genetics from University of Colorado Boulder.
“Andrew and Jennifer bring a wealth of experience to Catalent as we look to significantly grow our Biologics business,” commented Jonathan Arnold, Vice President & General Manager of Catalent Biologics. “Andrew has successfully launched biologics technology platforms in his previous roles and this will prove invaluable in support of our SMARTag technology. Jennifer has experience in drug development and has been a customer of Catalent’s proprietary GPEx technology for more than 10 years.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance